Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Type 1 Diabetes (DEPICT-1)
NCT02268214Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in type 1 diabetes mellitus (T1D) (3 arms), sponsored by AstraZeneca. Primary endpoint: Adjusted Mean Change in HbA1c From Baseline at 24 weeks. Started Nov 2014; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02268214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268214.